{"prompt": "['TABLE OF CONTENTS', 'INVESTIGATOR AGREEMENT', '2', 'CONTACT INFORMATION', '3', 'PROTOCOL SYNOPSIS', '9', 'LIST OF ABBREVIATIONS AND TERMS', '13', 'List of Abbreviations', '13', 'List of Terms and Definitions', '14', '1.', 'BACKGROUND', '16', '1.1.', 'Rationale', '17', '2.', 'STUDY DRUG AND DELIVERY SYSTEM', '19', '2.1.', 'Study Product', '19', '2.1.1.', 'Study Drug - Sodium Tetradecyl Sulfate (STS)', '19', '2.1.2.', 'Delivery System - ClariVein R', '19', '3.', 'STUDY OBJECTIVE', '20', '3.1.', 'Objectives and Endpoints', '20', '4.', 'STUDY DESIGN', '22', '4.1.', 'Treatment Arms', '22', '4.2.', 'Study Periods', '22', '4.2.1.', 'Screening/Baseline Period', '23', '4.2.2.', 'Treatment Day', '23', '4.2.3.', 'Post Treatment Follow-up (FU) Period', '23', '4.2.4.', 'Definition of End of Study', '23', '4.2.5.', 'Study or Site Termination', '23', '5.', 'ELIGIBILITY CRITERIA', '24', '5.1.', 'Inclusion Criteria', '24', '5.2.', 'Exclusion Criteria', '24', '6.', 'TREATMENT OF PATIENTS', '27', '6.1.', 'Study Treatment', '27', '6.2.', 'Study Duration', '27', '6.3.', 'Potential Drug Interactions/Allergies', '27', '6.4.', 'Prior and Concomitant Treatment(s)/Therapy', '27', '6.5.', 'Prohibited Concomitant Procedures/Therapies/Medications', '28', '6.6.', 'Patient Numbering, Treatment Assignment or Randomization', '28', 'Page 5 of 101']['6.6.1.', 'Subject Numbering', '28', '6.6.2.', 'Double Blind - Study Drug', '28', '6.6.3.', 'Emergency Breaking of the Study Blind', '28', '6.7.', 'Preparation, Dispensing, and Storage of Clinical Supplies', '28', '6.8.', 'Study Drug and Device Accountability', '28', '7.', 'VISIT SCHEDULE AND ASSESSMENTS', '29', '7.1.', 'Study Visit Schedule and Assessments', '29', '7.2.', 'Pre-visit Patient Instructions', '31', '7.3.', 'Screening (Visit 1)', '31', '7.4.', 'Baseline (Visit 2)', '31', '7.5.', 'Day of Treatment (Visit 3)', '32', '7.5.1.', 'Prior to Treatment', '32', '7.5.2.', 'Treatment Procedure', '32', '7.6.', 'Post Treatment Follow up Period: Week 1, Week 6 and Week 12', '32', '7.7.', 'End of the Study for Patient', '32', '7.7.1.', 'Discontinuation of Study Treatment/Procedure', '33', '7.7.2.', 'Withdrawal of Consent', '33', '8.', 'ASSESSMENT TYPES', '34', '8.1.', 'Safety and Tolerability', '34', '8.2.', 'Efficacy Assessments', '35', '8.2.1.', 'Assessment of Symptoms', '35', '8.2.2.', 'Elimination of Saphenous Vein Reflux', '35', '8.2.3.', 'Improvement in Patient Symptoms', '35', '9.', 'WITHDRAWAL OF PATIENTS FROM THE STUDY', '36', '9.1.', 'Prior to Randomization and Treatment', '36', '9.2.', 'Post Randomization and Treatment', '36', '10.', 'SAFETY MONITORING DURING THE STUDY', '37', '10.1.', 'Vital Signs', '37', '10.2.', 'History/Varicose Vein History/Physical Examination', '37', '10.3.', 'Clinical Laboratory Safety Assessments', '37', '10.4.', 'Post-treatment Local Effects', '37', '10.5.', 'Identification and Description of Thromboembolic Events', '37', '10.6.', 'Assessment of Adverse Events', '37', 'Page 6 of 101']\n\n###\n\n", "completion": "END"}